Adjunctive Clindamycin for Cellulitis: C4C Trial.

PHASE4CompletedINTERVENTIONAL
Enrollment

410

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

March 31, 2016

Conditions
Cellulitis
Interventions
DRUG

Flucloxacillin

Intravenous or oral Flucloxacillin. Minimum dose 500mg four times each day. Target duration 5 days less pre-recruitment beta-lactam duration.

DRUG

Clindamycin

Clindamycin dose 300mg four times each day for 2 days, within 48 hours of commencing flucloxacillin. Clindamycin is over-encapsulated and externally identical to placebo.

DRUG

Placebo oral capsule

Placebo is externally identical to the over-encapsulated clindamycin and is taken four times each day for 2 days

Trial Locations (1)

BS2 8HW

University Hospitals Bristol NHS Foundation Trust, Bristol

All Listed Sponsors
collaborator

University of Bristol

OTHER

collaborator

Public Health England

OTHER_GOV

lead

University Hospitals Bristol and Weston NHS Foundation Trust

OTHER

NCT01876628 - Adjunctive Clindamycin for Cellulitis: C4C Trial. | Biotech Hunter | Biotech Hunter